PMID- 10457157
OWN - NLM
STAT- MEDLINE
DCOM- 19990922
LR  - 20190826
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 29
IP  - 8
DP  - 1999 Aug
TI  - Pneumocystis carinii major surface glycoprotein induces interleukin-8 and 
      monocyte chemoattractant protein-1 release from a human alveolar epithelial cell 
      line.
PG  - 717-22
AB  - BACKGROUND: The major surface glycoprotein (MSG) is an abundant, immunogenic 
      glycoprotein located on the surface of Pneumocystis carinii. Little is known 
      about the proinflammatory effects of MSG. DESIGN: We have investigated the effect 
      of human MSG on the secretion of the chemokines interleukin 8 (IL-8) and monocyte 
      chemoattractant protein-1 (MCP-1) from an alveolar epithelial cell line (A549). 
      RESULTS: Incubation of A549 cells with MSG in concentrations from 0.4 to 10 
      microg mL-1 for 24 h caused dose-dependent increases in IL-8 release (3.4-fold 
      above control, P < 0.01). Time course experiments showed increases in IL-8 
      release at 4 h, 8 h and 24 h compared with control cultures (all P < 0.01). There 
      was a minor (13%) dose- and time-related increase in MCP-1 release at 24 h (P = 
      0.02). Co-incubation of MSG with mannan or beta-glucan decreased IL-8 release by 
      48% and 42% respectively, suggesting that MSG stimulates A549 cells in part 
      through carbohydrate moieties. Dexamethasone significantly inhibited MSG-induced 
      IL-8 release in concentrations of 10-6-10-8 mol L-1 compared with control 
      experiments (P < 0.01). Ribonuclease protection assays for steady-state IL-8 mRNA 
      showed that increases in response to MSG stimulation occurred by 4 h and 
      persisted throughout 8 h of stimulation. CONCLUSION: These findings suggest that 
      MSG can alter alveolar epithelial cytokine release and may be capable of 
      modulating the local inflammatory response in this manner.
FAU - Benfield, T L
AU  - Benfield TL
AD  - University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark. 
      tbenfield@inet.uni2.dk
FAU - Lundgren, B
AU  - Lundgren B
FAU - Shelhamer, J H
AU  - Shelhamer JH
FAU - Lundgren, J D
AU  - Lundgren JD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Chemokine CCL2)
RN  - 0 (Fungal Proteins)
RN  - 0 (Glucans)
RN  - 0 (Glucocorticoids)
RN  - 0 (Interleukin-8)
RN  - 0 (Mannans)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (RNA, Messenger)
RN  - 151472-24-1 (GPA protein, Pneumocystis carinii sp.)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Cell Line
MH  - Chemokine CCL2/*metabolism
MH  - Dexamethasone/pharmacology
MH  - Epithelial Cells/immunology
MH  - Fungal Proteins/administration & dosage/immunology/*toxicity
MH  - Glucans/administration & dosage
MH  - Glucocorticoids/pharmacology
MH  - Humans
MH  - Interleukin-8/genetics/*metabolism
MH  - Mannans/administration & dosage
MH  - Membrane Glycoproteins/administration & dosage/immunology/*toxicity
MH  - Pneumocystis/immunology/*pathogenicity
MH  - Pulmonary Alveoli/immunology
MH  - RNA, Messenger/biosynthesis/genetics
MH  - Up-Regulation/drug effects
EDAT- 1999/08/24 00:00
MHDA- 1999/08/24 00:01
CRDT- 1999/08/24 00:00
PHST- 1999/08/24 00:00 [pubmed]
PHST- 1999/08/24 00:01 [medline]
PHST- 1999/08/24 00:00 [entrez]
AID - eci517 [pii]
AID - 10.1046/j.1365-2362.1999.00517.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 1999 Aug;29(8):717-22. doi: 10.1046/j.1365-2362.1999.00517.x.